246
Views
14
CrossRef citations to date
0
Altmetric
Research Article

Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model

, , , , , , , & show all
Pages 138-144 | Received 07 May 2013, Accepted 04 Jun 2013, Published online: 17 Jul 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Mimbay Yaşar, Harun Çakmak, Sema Dündar, Seda Örenay Boyacıoğlu, Metin Çalışkan & Kemal Ergin. (2020) The role of microRNAs in corneal neovascularization and its relation to VEGF. Cutaneous and Ocular Toxicology 39:4, pages 341-347.
Read now
Ling Chen, Jing Zhong, Saiqun Li, Weihua Li, Bowen Wang, Yuqing Deng & Jin Yuan. (2018) The long-term effect of tacrolimus on alkali burn-induced corneal neovascularization and inflammation surpasses that of anti-vascular endothelial growth factor. Drug Design, Development and Therapy 12, pages 2959-2969.
Read now
Huseyin Guzel, Berker Bakbak, Mehmet Talay Koylu, Saban Gonul, Banu Ozturk & Sansal Gedik. (2017) The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema. Cutaneous and Ocular Toxicology 36:1, pages 5-8.
Read now
Harun Çakmak, Kemal Ergin, Gökay Bozkurt, Tolga Kocatürk & Gökhan Evren Evliçoğlu. (2016) The effects of topical everolimus and sunitinib on corneal neovascularization. Cutaneous and Ocular Toxicology 35:2, pages 97-103.
Read now

Articles from other publishers (10)

Michael Mimouni & Dean Ouano. (2022) Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization. International Ophthalmology 42:8, pages 2407-2416.
Crossref
MT Eski, Kuddusi Teberik, Pembe Oltulu, Handan Ankaralı, Murat Kaya & Merve Alpay. (2022) The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization. Human & Experimental Toxicology 41, pages 096032712210846.
Crossref
Alireza Baradaran-Rafii, Azin Ashnagar, Saeed Heidari Keshel, Sayena Jabbehdari & Ghazaleh Baradaran-Rafii. (2019) Regression of corneal neovascularization: Adiponectin versus bevacizumab eye drops. European Journal of Ophthalmology 31:1, pages 78-82.
Crossref
Guanyu Su, Zhenyu Wei, Leying Wang, Jing Shen, Christophe Baudouin, Antoine Labbé & Qingfeng Liang. (2020) Evaluation of Toluidine Blue-Mediated Photodynamic Therapy for Experimental Bacterial Keratitis in Rabbits. Translational Vision Science & Technology 9:3, pages 13.
Crossref
Danial Roshandel, Medi Eslani, Alireza Baradaran-Rafii, Albert Y. Cheung, Khaliq Kurji, Sayena Jabbehdari, Alejandra Maiz, Setareh Jalali, Ali R. Djalilian & Edward J. Holland. (2018) Current and emerging therapies for corneal neovascularization. The Ocular Surface 16:4, pages 398-414.
Crossref
Yanling Song, Qiujie Song, Ling Li, Jinfeng Xu & Xingqiang Liu. (2018) Effect of ranibizumab on levels of IL-6 and VEGF in peripheral blood and aqueous humor of glaucoma rat model and association of IL-6 and VEGF with optic nerve damage. Experimental and Therapeutic Medicine.
Crossref
Xinyao Liu, Shurong Wang, Xuanzhong Wang, Jiaming Liang & Yan Zhang. (2017) Recent drug therapies for corneal neovascularization. Chemical Biology & Drug Design 90:5, pages 653-664.
Crossref
Sayena Jabbehdari, Alireza Baradaran-Rafii, Ghasem Yazdanpanah, Pedram Hamrah, Edward J. Holland & Ali R Djalilian. (2017) Update on the Management of High-Risk Penetrating Keratoplasty. Current Ophthalmology Reports 5:1, pages 38-48.
Crossref
Ruti Sella, Orly Gal-Or, Eitan Livny, Mor Dachbash, Yael Nisgav, Dov Weinberger, Tami Livnat & Irit Bahar. (2016) Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model. Experimental Eye Research 146, pages 224-232.
Crossref
Chih-Chien Hsu, Hua-Ming Chang, Tai-Chi Lin, Kuo-Hsuan Hung, Ke-Hung Chien, Szu-Yu Chen, San-Ni Chen & Yan-Ting Chen. (2015) Corneal neovascularization and contemporary antiangiogenic therapeutics. Journal of the Chinese Medical Association 78:6, pages 323-330.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.